|
Acute Promyelocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with hypogranular variant APL were differed from classical APL by co-expression of CD2 and CD34.
|
30002801 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sensitivity, specificity, and positive predictive value (PPV) of CD34-/HLA-DR- and HLA-DR-/CD11b- profiles for the diagnosis of APL were found to be 90%, 80% & 81.1% and 93.3%, 86.7%& 87.5%, respectively.
|
28984423 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of 84 cases (63%) that lacked monocytic differentiation ("myeloid AML"), 40 (48%) demonstrated an acute promyelocytic leukemia-like (APL-like) immunophenotype by flow cytometry, with absence of CD34 and HLA-DR and strong myeloperoxidase expression, in the absence of a PML-RARA translocation.
|
29274134 |
2018 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, the mechanism of TSY-1 on cellular Telomerase activity was further investigated using HL60, a promyelocytic leukemia cell line, normal peripheral blood mononuclear cells, and CD34+ hematopoietic stem cells derived from umbilical cord blood.
|
28002788 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Common myeloid progenitors (CMP) from CD34(+)/CD38(+) cells developed APL.
|
25369030 |
2014 |
|
Acute Promyelocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The objective of the study is to compare antigenic expression in a group of APL patients with that in AML patients with NPM mutations and an APL-like immunophenotype (CD15- CD34- HLA-DR-).
|
21812014 |
2012 |
|
Acute Promyelocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Even in the CD34(pos) subgroup of HLA-DR(neg) non-APL all those features contributed in at least the same way to the separation from APL.
|
19291801 |
2009 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a novel sorting strategy we developed to isolate murine myeloid cells at distinct stages of differentiation, we identified a population of committed myeloid cells (CD34(+), c-kit(+), FcgammaRIII/II(+), Gr1(int)) that accumulates in the spleen and bone marrow in a murine model of APL.
|
19797526 |
2009 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positive and negative predictive values of HLA-DR and CD34 in the diagnosis of acute promyelocytic leukemia and other types of acute myeloid leukemia with recurrent chromosomal translocations.
|
20232575 |
2009 |
|
Acute Promyelocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found nine miRNAs overexpressed and three miRNAs (miR-107, -342 and let-7c) downregulated in APL blasts as compared with normal promyelocytes differentiated in vitro from CD34+ progenitors.
|
19749800 |
2009 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
LHGDN |
Comparative analysis of cell surface proteins in chronic and acute leukemia cell lines.
|
17449014 |
2007 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of PDCD4 was markedly up-regulated during all-trans retinoic acid (ATRA)-induced granulocytic differentiation in NB4 and HL60 AML cell lines and in primary human promyelocytic leukemia (AML-M3) and CD34(+) hematopoietic progenitor cells but not in differentiation-resistant NB4.R1 and HL60R cells.
|
17259349 |
2007 |
|
Acute Promyelocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the 136 APL cases, 24 (17.6%) and 80 (58.8%) were identified as CD34+CD2+ and CD34-CD2-, respectively.
|
16531253 |
2006 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
S-form APL (n = 45) had a higher percent of cells expressing CD2 or CD34 (P < 0.0001 for both) or the neural cell adhesion molecule CD56 (P = 0.001) than L-form APL (n = 66).
|
15108165 |
2004 |
|
Acute Promyelocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, CD34 expression in APL is a unique clinical feature associated with leukocytosis and atypical morphology with hypogranular pattern and is associated with a poor clinical outcome.
|
12827650 |
2003 |
|
Acute Promyelocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
In conclusion, CD34 expression in APL is a unique clinical feature associated with leukocytosis and atypical morphology with hypogranular pattern and is associated with a poor clinical outcome.
|
12827650 |
2003 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
By liquid culture of leukemia cell lines and fresh AML cells with the addition of all-trans retinoic acid (ATRA), modulation of P-gp/MDR1 and Egr1 was observed and the pattern of modulation was divided into four groups: (1) blastic AML type, in which distinct expression of P-gp/MDR1 and CD34 was not influenced by ATRA; (2) t(8;21)AML type, in which P-gp/MDR1 expression was augmented by ATRA, while CD34 was kept high; (3) AML M3 type, in which P-gp/MDR1 expression was reduced with granulocytic differentiation by ATRA; (4) monocytic AML type, in which P-gp/MDR1 expression was augmented by ATRA, while CD34 expression decreased, and strong Egr1 expression was downregulated just prior to the augmentation of P-gp/MDR1 expression.
|
11734301 |
2002 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe a variant form, French-American-British (FAB) M3v, of acute promyelocytic leukemia (APL; FAB M3) with atypical morphocytochemical features, immature antigens (CD34 and HLA-DR) and marked myelofibrosis (MF).
|
11721970 |
2001 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The knowledge that APL may be partly or largely CD34+ is important for proper diagnosis.
|
10587705 |
1999 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This report describes a unique case of acute promyelocytic leukemia (APL) showing elusive morphologic features, an atypical pattern of cytochemical reactions, and a previously unreported immunophenotype consistent with a very early myeloid form: CD13 (+), CD33 (+), CD9 (+), CD2 (+), HLA-DR (-), CD34 (+), CD117 (+), and TdT (+).
|
9279368 |
1997 |
|
Acute Promyelocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of MRP expression in newly diagnosed AML samples were similar to those observed in normal bone marrow cells (CD34-negative and CD34-positive) and in unselected HL60 human promyelocytic leukemia cells, which were used as an internal control throughout this study.
|
7528566 |
1995 |
|
Acute Promyelocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast to non-APL leukemias, those few cases of CD34 strongly positive APL neither expressed Pgp nor contained significant MDR1 transcript levels.
|
7516029 |
1994 |